Cancer Institute– A national cancer institute
designated cancer center

Alan Yeung, MD

Back to Profile

Publication Details

  • Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.

    Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ. Circulation. 2001; 104 (10): 1188-93

    The purpose of this study was to determine the efficacy of stent-based delivery of sirolimus (SRL) alone or in combination with dexamethasone (DEX) to reduce in-stent neointimal hyperplasia. SRL is a potent immunosuppressive agent that inhibits SMC proliferation by blocking cell cycle progression.

    PubMedID: 11535578

Stanford Medicine Resources:

Footer Links: